ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
about
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer CellsQuick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
P2860
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
ALT-803, an IL-15 superagonist ...... d, open-label, phase 1b trial.
@en
ALT-803, an IL-15 superagonist ...... d, open-label, phase 1b trial.
@nl
type
label
ALT-803, an IL-15 superagonist ...... d, open-label, phase 1b trial.
@en
ALT-803, an IL-15 superagonist ...... d, open-label, phase 1b trial.
@nl
prefLabel
ALT-803, an IL-15 superagonist ...... d, open-label, phase 1b trial.
@en
ALT-803, an IL-15 superagonist ...... d, open-label, phase 1b trial.
@nl
P2093
P2860
P50
P1433
P1476
ALT-803, an IL-15 superagonist ...... d, open-label, phase 1b trial.
@en
P2093
Amy D Rock
Andie R Edwards
Carol Sherman
Carsten Krieg
Catherine M Sanders
Elizabeth G Hill
Elizabeth Garrett-Mayer
Emily K Jeng
Erik C Yusko
P2860
P304
P356
10.1016/S1470-2045(18)30148-7
P577
2018-04-05T00:00:00Z